AML

(redirected from Acute myeloid leukaemia)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to Acute myeloid leukaemia: Chronic myeloid leukaemia, Acute lymphoblastic leukaemia

Adjustable Rate Mortgage

A mortgage with an interest rate that changes periodically. Generally speaking, an adjustable rate mortgage is linked to some major benchmark rate; for example, the interest rate may be stated as "LIBOR + 1%." The mortgage may or may not have a cap on how much the interest rate can rise or fall, or on how often the interest rate may change. Very often, the initial interest rate for an adjustable-rate mortgage is lower than that for a fixed-rate mortgage. This allows more people to qualify for an adjustable-rate mortgage; however, this kind of mortgage can be risky because the interest rate (and therefore the monthly payment) can rise unexpectedly. Indeed the prevalence of ARMs has been blamed for the housing bubble in the mid-2000s and the subsequent recession. See also: Credit Crunch, Teaser Rate.

Anti-Money Laundering

Any law or regulation requiring an institution to perform due diligence on potential clients to ensure that it is not aiding in a money laundering scheme. If the institution does not conduct due diligence properly, it may be held legally liable for the money laundering activities. These regulations were an important part of the USA PATRIOT Act.

AML

See adjustable mortgage loan.
References in periodicals archive ?
FAB classification of acute myeloid leukaemia is still commonly used in our country because of its good reproducibility and easy application even in under resourced laboratories6,7.
Acute Myeloid Leukaemia Phase 2 Clinical Trial Pipeline Insights
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukaemia (AML): a survey of 161 cases from the French AML Intergroup.
The new research has shown that mutation in NPM1 is a key event in the development of a large proportion of cases of acute myeloid leukaemia and that it exerts its effect by helping cells to self-renew, a process that can be thought of as the first step towards leukaemia.
Early data from the relapsed or refractory acute myeloid leukaemia patients in this study were presented at the 2015 American Society of Hematology Annual Meeting.
The main aim of the trial is to analyse safety, additional endpoints including mobilisation of acute myeloid leukaemia blasts, effect on neutropenia, time to and duration of remission, evaluation of event-free survival and evaluation of the overall survival probability at six- and 12-months.
Presently, the firm is enrolling patients in an open-label multicentre Phase I/II trial, which is designed to assess the safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in adult patients with acute myeloid leukaemia.
The contract has been signed to conduct an E6201 Phase I/IIa clinical trial in patients with advanced hematologic malignancies, including acute myeloid leukaemia.
for the treatment of adult and pediatric acute lymphoblastic leukaemia and acute myeloid leukaemia.
United Kingdom-based Oxford BioTherapeutics in collaboration with Italy-based Menarini Group have commenced the first-in-human clinical trial of OBT357 (MEN1112), a new improved antibody to treat acute myeloid leukaemia, it was reported yesterday.
The filing was based on data from two pivotal Phase II trials in acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) which will be presented at the 40th American Society of Clinical Oncology annual meeting in June.
BerGenBio, a Norway-based biopharmaceutical company, has received orphan-drug designation from the US Food and Drug Administration for its BGB324 to treat acute myeloid leukaemia, it was reported on Thursday.
Full browser ?